Table 3.
Systemic therapy within 6 months post diagnosis for stage IV non-squamous NSCLC according to region
| Treatment | Region |
Total | |||
|---|---|---|---|---|---|
| Lampanga | Penangb | Singaporec | Yogyakarta | ||
| Cases (N) | 374 | 184 | 647 | 323 | 1528 |
| Chemotherapy, n (%) | |||||
| Yes | 151 (40.4) | 49 (26.6) | 118 (18.2) | 77 (23.8) | 395 (25.9) |
| No | 216 (57.8) | 130 (70.7) | 527 (81.5) | 235 (72.8) | 1108 (72.5) |
| Unknown | 7 (1.9) | 5 (2.7) | 2 (0.3) | 11 (3.4) | 25 (1.6) |
| Targeted therapy, n (%) | |||||
| Yes | 26 (7.0) | 52 (28.3) | 369 (57.0) | 97 (30.0) | 544 (35.6) |
| No | 343 (91.7) | 130 (70.7) | 276 (42.7) | 215 (66.6) | 964 (63.1) |
| Unknown | 5 (1.3) | 2 (1.1) | 2 (0.3) | 11 (3.4) | 20 (1.3) |
| Immunotherapy, n (%) | |||||
| Yes | 3 (0.8) | 4 (2.2) | 83 (12.8) | 0 (0) | 90 (5.9) |
| No | 363 (97.1) | 174 (94.6) | 562 (86.9) | 309 (95.7) | 1,408 (92.1) |
| Unknown | 8 (2.1) | 6 (3.3) | 2 (0.3) | 14 (4.3) | 30 (2.0) |
| None, n (%) | 189 (50.5) | 77 (41.8) | 75 (11.6) | 138 (42.7) | 479 (31.3) |
| Unknown treatment, n (%) | 5 (1.3) | 2 (1.1) | 2 (0.3) | 11 (3.4) | 20 (1.3) |
NSCLC, non-small-cell lung cancer.
a
One case reported a combination of first-line chemotherapy and immunotherapy.
b
One case reported a combination of first-line chemotherapy and targeted therapy, two cases reported a combination of chemotherapy and immunotherapy.
c
One case reported a combination of first-line chemotherapy and targeted therapy, 41 cases reported a combination of chemotherapy and immunotherapy.